Earnings Feed
Start Free
Home/Filings/4/0001140361-17-047825
4//SEC Filing

Traweek James W JR 4

Accession 0001140361-17-047825

CIK 0001358762other
View on SEC.govCompany Profile

Filed

Dec 28, 7:00 PM ET

Accepted

Dec 29, 5:12 PM ET

Size

10.6 KB

Accession

0001140361-17-047825

Insider Transaction Report

Form 4
Period: 2017-12-29
REATA PHARMACEUTICALS INCRETA
Traweek James W JR
10% Owner
Transactions
  • Purchase

    Class A common stock

    2017-12-29$28.47/sh+17,000$484,016→ 2,912,523 total(indirect: See Footnote)
Holdings

  • Class A common stock

    (indirect: By Trust)
    572

  • Class A common stock

    35

  • Class A common stock

    (indirect: By JET Land & Cattle Company, Ltd.)
    16,645

  • Class A common stock

    (indirect: By Trust)
    572

  • Class A common stock

    (indirect: By Trust)
    7,056

  • Class A common stock

    (indirect: See footnote)
    2,739
Footnotes (8)
  • [F1]These shares of Class A common stock are held in various funds for which CPMG, Inc. serves as investment manager. The Reporting Person is a co-director and co-shareholder of CPMG, Inc.
  • [F2]The Reporting Person is the sole owner of the general partner of JET Land & Cattle Company, Ltd.
  • [F3]The Reporting Person is trustee of 1 Thessalonians 5:18 Trust.
  • [F4]The Reporting Person is trustee of Esme Grace McGaughy Trust.
  • [F5]The Reporting Person is trustee of Mary Frances McGaughy Trust.
  • [F6]These shares of Class A common stock are held in escrow for a charitable donee by American Stock Transfer & Trust Company, LLC.
  • [F7]The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
  • [F8]This price reflects the weighted average purchase price for open-market purchases on December 29, 2017, within a $1.00 range. The actual prices for these transactions range from $28.40 to $28.50 inclusive. The Reporting Person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price within the range set forth in this footnote (8) to this Form 4.

Documents

1 file

Issuer

REATA PHARMACEUTICALS INC

CIK 0001358762

→
Entity typeother

Related Parties

1
  • filerCIK 0001665299

Filing Metadata

Form type
4
Filed
Dec 28, 7:00 PM ET
Accepted
Dec 29, 5:12 PM ET
Size
10.6 KB
View on SEC.gov